S

Shionogi

Specialty pharma marketing pain and anti-infectives

Overview

Shionogi expanded its U.S. portfolio by acquiring Victory Pharma’s marketed products, adding pain medications and anti-infectives to its lineup. The products include Naprelan for pain and anti-infectives like MOXATAG and KEFLEX, which Shionogi’s existing U.S. sales force markets to doctors. The move paired a pain-focused line with infectious-disease drugs to balance seasonal demand and reach pain specialists, rheumatologists, orthopedic surgeons, and some primary care physicians. The goal was to grow Shionogi’s presence in U.S. pain management and infectious diseases by integrating Victory Pharma’s products into its sales and marketing engine, though Victory Pharma later faced a federal settlement related to promotional practices.

Significant Headcount Growth

Work here?Claim your company

About Shionogi

Simplify's Rating
Why Shionogi is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

Florham Park, NJ

Founded

2001

Get referred to Shionogi

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • SCORPIO-PEP cut symptomatic COVID-19 by 67%, creating immediate U.S. launch momentum.
  • Radicava adds roughly $700 million annual sales, immediately accretive in fiscal 2026.
  • February 13, 2026 reorganization and April 1, 2027 Torii merger tighten operations.

What critics are saying

  • XOCOVA depends on transient exposure-driven demand; sales fade as COVID waves normalize.
  • Radicava's $2.5 billion price amplifies concentration risk if ALS uptake stalls.
  • Shionogi's 2026 growth rests on two launches; one miss leaves earnings entirely Japan-bound.

What makes Shionogi unique

  • Shionogi controls XOCOVA, FDA-approved June 1, 2026, first oral COVID-19 post-exposure prophylaxis.
  • April 2, 2026 Radicava acquisition gave Shionogi global ALS rights and commercial infrastructure.
  • Shionogi pairs infectious-disease depth with Japan-U.S. manufacturing and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$7.6M

Above

Industry Average

Funded Over

2 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison Coming Soon

Benefits

  • Performance Bonus
  • 401(k) Retirement Plan
  • 401(k) Company Match

Stock Price

Growth & Insights and Company News

6 month growth

10%

1 year growth

10%

2 year growth

10%
Industry Events
Oct 29th, 2026
Shionogi wins NEDO award for quantum-assisted drug discovery.

Shionogi wins NEDO award for quantum-assisted drug discovery. Insider Brief PRESS RELEASE - D-Wave Quantum Inc. (NASDAQ: QBTS) ("D-Wave"), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that its customer Shionogi & Co., Ltd. ("Shionogi") has won first place in the Quality of Life (QOL) category of the NEDO Challenge for its research exploring [...] By The Quantum Insider Got news to share with the events industry? More in Quantum Tech & Cryptography. Related insights. Relevant events. Events in Quantum Tech & Cryptography

MarketBeat
Oct 28th, 2026
D-Wave Quantum (NASDAQ:QBTS) shares down 3% - should you Sell?

D-Wave Quantum (NASDAQ:QBTS) shares down 3% - should you Sell? October 28, 2026 Key points. * D-Wave Quantum shares fell 3% to $11.77 amid sector-wide selling, higher-rate concerns and valuation worries, with trading volume below its average. * The company has announced potentially positive developments, including an enterprise-focused partnership with South Korea's LG CNS and third-party recognition of customer Shionogi's quantum drug-discovery work, though the LG agreement does not guarantee revenue. * Investors face significant risks ahead of the November 10 earnings report, including ongoing losses, a prior revenue and EPS miss, heavy investment needs and a newly publicized securities class action. Analysts remain broadly bullish, with a $36.27 consensus target, but one brokerage downgraded the stock to "hold." * MarketBeat previews the top five stocks to own by November 1st. D-Wave Quantum Inc. (NASDAQ:QBTS - Get Free Report) shares dropped 3% on Wednesday. The stock traded as low as $11.50 and last traded at $11.77. Approximately 13,809,134 shares were traded during trading, a decline of 46% from the average session volume of 25,784,371 shares. The stock had previously closed at $12.13. More D-Wave Quantum news. Here are the key news stories impacting D-Wave Quantum this week: * D-Wave signed a non-binding memorandum of understanding with South Korea's LG CNS to pursue enterprise quantum-optimization use cases and expand adoption in the Asian market. The partnership could support future commercial activity, although the agreement does not guarantee revenue. * D-Wave customer Shionogi won first place in the Quality of Life category of Japan's NEDO Quantum Computing Challenge for drug-discovery research, providing third-party validation of D-Wave's technology and potential healthcare applications. * D-Wave will report third-quarter 2026 results before the market opens on November 10. Investors will be watching bookings, revenue growth, cash usage and losses after the company's prior quarter missed consensus revenue and EPS estimates. * Brokerages reportedly have an average price target of $36.27, but that target contrasts with concerns that QBTS may already reflect substantial future growth after its dramatic multiyear rally. * Multiple law firms publicized a securities class action alleging that D-Wave and certain executives made misleading statements about growth prospects during the February 26-August 25, 2026 class period. Investors have until December 15, 2026 to seek lead-plaintiff status, adding legal and reputational overhang. * Analysts cited sector-wide selling and higher-rate caution as immediate reasons for the stock's decline. Separate valuation commentary argues that QBTS looks fully priced relative to its financial performance, including continuing losses and heavy investment needs. Analysts set new price targets. Several brokerages have recently commented on QBTS. Zacks Research lowered shares of D-Wave Quantum from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 18th. Jefferies Financial Group set a $40.00 price objective on shares of D-Wave Quantum in a research note on Friday, August 7th. Wedbush assumed coverage on shares of D-Wave Quantum in a report on Monday, August 3rd. They issued an "outperform" rating and a $40.00 price objective for the company. Weiss Ratings raised shares of D-Wave Quantum from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 28th. Finally, Roth Capital restated a "buy" rating and set a $30.00 target price on shares of D-Wave Quantum in a report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.27. Discover more MarketBeat All Access MarketBeat Research Tools D-Wave Quantum stock performance. The firm has a 50 day moving average of $15.92 and a two-hundred day moving average of $19.64. The stock has a market cap of $4.35 billion, a P/E ratio of -16.58 and a beta of 2.18. The company has a debt-to-equity ratio of 0.03, a quick ratio of 20.42 and a current ratio of 20.55. D-Wave Quantum (NASDAQ:QBTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). D-Wave Quantum had a negative return on equity of 26.67% and a negative net margin of 2,001.59%. The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $4.03 million. During the same period in the prior year, the firm earned ($0.08) earnings per share. The business's quarterly revenue was down 0.6 on a year-over-year basis. On average, research analysts predict that D-Wave Quantum Inc. will post -0.46 EPS for the current fiscal year. Institutional investors weigh in on D-Wave Quantum. Hedge funds have recently made changes to their positions in the stock. Fiduciary Financial Advisors bought a new position in D-Wave Quantum in the second quarter worth $25,000. Parallel Advisors LLC raised its stake in shares of D-Wave Quantum by 545.5% in the 1st quarter. Parallel Advisors LLC now owns 1,788 shares of the company's stock valued at $26,000 after buying an additional 1,511 shares in the last quarter. Adirondack Trust Co. raised its stake in shares of D-Wave Quantum by 267.3% in the 3rd quarter. Adirondack Trust Co. now owns 1,649 shares of the company's stock valued at $27,000 after buying an additional 1,200 shares in the last quarter. PeakShares LLC bought a new position in shares of D-Wave Quantum during the 1st quarter worth about $29,000. Finally, Latitude Advisors LLC bought a new position in shares of D-Wave Quantum during the 3rd quarter worth about $38,000. Institutional investors own 42.47% of the company's stock. About D-Wave Quantum. D-Wave Quantum Inc NASDAQ: QBTS is a quantum computing company that develops and provides quantum computing systems, software, and related services. The company focuses on both quantum annealing and gate-model quantum computing, with the goal of helping organizations address complex optimization, artificial intelligence, materials science, cybersecurity, and other computational challenges. Its product portfolio includes quantum computing systems, hybrid quantum-classical solutions, and the Leap quantum cloud service, which gives customers access to D-Wave systems through the cloud. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider D-Wave Quantum, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and D-Wave Quantum wasn't on the list. While D-Wave Quantum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power. Continue following MarketBeat

FilingReader
Oct 5th, 2026
Shionogi to acquire IntraBio for $2.0bn.

Shionogi to acquire IntraBio for $2.0bn. October 5, 2026 at 06:10 AM UTC - By FilingReader AI Shionogi & Co., Ltd. has announced an agreement for its U.S. subsidiary to acquire IntraBio Inc. as a wholly owned subsidiary for an upfront consideration of $2.0bn, with the transaction scheduled between November and December 2026. The transaction adds IntraBio's rare disease portfolio, highlighted by AQNEURSA, to Shionogi's growing capabilities in rare neurodegenerative and genetic neurological diseases. AQNEURSA is approved in the U.S. and EU for Niemann-Pick disease type C and recently received FDA approval for treating Ataxia-Telangiectasia. Additionally, the acquisition brings clinical programs targeting Pompe disease, Fragile X syndrome, and Jordan's syndrome into the company's pipeline. This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact [email protected] TSE:4507 - Tokyo Stock Exchange Get instant email alerts when Shionogi & publishes news Free account required - Unsubscribe anytime Filing activity timeline. October 4, 2026 This News Filings (90 days): 14 documents Most recent: Oct 4

Qpex Biopharma
Sep 9th, 2026
Shionogi to showcase advancements across its infectious disease portfolio at IDWeek 2026.

Shionogi to showcase advancements across its infectious disease portfolio at IDWeek 2026. Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C. Data highlights at IDWeek 2026 include an oral presentation featuring a subpopulation analysis from the global Phase 3 SCORPIO-PEP trial, a rapid-fire session focused on ventilator-associated pneumonia isolates from the SENTRY Antimicrobial Surveillance Program and 18 additional presentations across Shionogi's COVID-19 antiviral and Gram-negative antibiotic programs.

MarketBeat
Aug 29th, 2026
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) short interest update.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) short interest update. August 29, 2026 Key points. * Short interest fell 49.6% to 3,812 shares as of August 14, representing effectively 0.0% of shares outstanding and a 0.0-day short-interest ratio. * Shionogi reported quarterly EPS of $0.36, beating estimates of $0.18, while revenue of $1.04 billion exceeded the $970.69 million consensus forecast. * Analyst sentiment improved, with Jefferies and Goldman Sachs upgrading the ADR to "strong buy"; MarketBeat lists an overall average rating of "Buy." * MarketBeat previews top five stocks to own in September. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 3,812 shares, a decline of 49.6% from the July 30th total of 7,564 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 150,205 shares, the short-interest ratio is currently 0.0 days. Shionogi & Co., Ltd. Unsponsored ADR stock down 0.6%. Shares of SGIOY stock opened at $9.04 on Friday. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $7.65 and a one year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock has a fifty day moving average price of $8.85 and a 200 day moving average price of $9.76. The stock has a market cap of $15.39 billion, a P/E ratio of 9.04, a price-to-earnings-growth ratio of 3.36 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current year. Institutional inflows and outflows. An institutional investor recently bought a new stake in Shionogi & Co., Ltd. Unsponsored ADR stock. Birmingham Capital Management Co. Inc. AL purchased a new position in shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,950 shares of the company's stock, valued at approximately $257,000. Hedge funds and other institutional investors own 1.92% of the company's stock. Analysts set new price targets. Several research firms recently commented on SGIOY. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 14th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "strong sell" rating to a "hold" rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy". Discover more Options Profit Calculator AI Infrastructure Stocks Stock Split Calculator Shionogi & Co., Ltd. Unsponsored ADR company profile. Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders. The company's product portfolio spans both established and innovative therapies. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list. While Shionogi & Co., Ltd. Unsponsored ADR currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Recently Posted Jobs

Sign up to get curated job recommendations

Shionogi is Hiring for 53 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs